Protein MetabolismNCT06628349
Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein
A study testing Whey Protein Isolate 90%, Soy Protein Isolate (90% Protein) and Organic Pea Protein Isolate in people with Protein Metabolism, run by Texas A&M University at 1 site in United States.
Trial summary
The researchers overall objective is to determine whether plant and animal protein based proteins affect the anabolic responses across aging populations differently due to specific changes in the essential amino acids (EAA) and non-essential amino acids (NEAA) kinetic responses. Read more about this study
- Who is it for?
- Ages 50 to 95 yearsHealthy volunteers can take part
- Conditions the study is for
- Protein Metabolism
- What is being tested?
- Whey Protein Isolate 90%, Soy Protein Isolate (90% Protein) and Organic Pea Protein Isolate
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2024to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 95 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 50-95 years old
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD); COPD group only
- Stable body-weight (±5%) for the past 3 months
- Ability to walk, sit down, and stand up (independently or with walking assistance device)
- Willingness to lay supine in bed for up to 6 hours
- Willingness and ability to comply with the protocol
Who cannot join
- Established diagnosis and active treatment of chronic disease: Insulin dependent diabetes mellitus, active malignancy, heart disease, kidney disease, liver disease, HIV/AIDS, Asthma (moderate to severe), Hep (A,B, or C)
- History of untreated metabolic disease including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Hysterectomy
- Active dependence of alcohol or drugs
- Use of short course of oral corticosteroids within 4 weeks preceding study day
Show all 17Show fewer
- Current use of long-term oral corticosteroids
- Use of protein or amino acids containing nutritional supplements within 5 days of the first study day
- Presence of fever within the last 3 days
- Planned elective surgery requiring 2 or more days of hospitalization during the entire study
- (Possible) pregnancy
- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject
- Already enrolled in another clinical trial
- Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
- Known allergy to any of the components of the feeding (soy, pea, or whey - dairy)
- Established daily diet of vegetarian / vegan composition
- <23 MoCa score
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Texas A&M University - CTRAL
College Station, Texas, 77845
Laura Ruebush, 979-218-5515, le.ruebush@ctral.org
Nicolaas E Deutz, MD, PhD
About this study
The researchers overall objective is to determine whether plant and animal protein based proteins affect the anabolic responses across aging populations differently due to specific changes in the essential amino acids (EAA) and non-essential amino acids (NEAA) kinetic responses. The researchers central hypothesis is that a high EAA to NEAA ratio in a protein meal is related to higher anabolic response to the meal. The researchers also hypothesize that the type of NEAA in a protein meal also affects the anabolic capacity of the meal. The researchers rationale is that finding the amino acid composition of a meal that will maximally induce protein anabolism will guide novel nutritional approaches to prevent and treat sarcopenia, thereby reducing both overall economic burden and improving individual patient outcomes.
Read the detailed description
The study will be conducted in sarcopenic and non-sarcopenic older adults, stratified into different age categories. A sip feeding model will be used as it is a good model to establish the anabolic capacity of meals. The researchers hypothesize that plant-based protein induces less protein anabolism, due to lower production of EAA and higher production of non-essential amino acids (NEAA) as compared to dairy protein. The NEAA kinetics will be different between the plant proteins as soy protein has relatively high levels of the NEAA arginine and Pea protein of aspartate/glutamate. The researchers results will guide future nutritional advice on replacing daily protein with plant-based proteins while keeping the overall effects on metabolism comparable for both the EAA and NEAA. The study will take place at the research facility of the Center for Translational Research on Aging and Longevity (CTRAL), Texas A\&M University located in the Human Clinical Research Building ) affiliated with Texas A\&M University. The study involves 1 screening visit of approx. 3 hours, and 4 study days. Some study procedures (e.g., body composition, skeletal muscle function, questionnaires) may be skipped if completed within the past 3 months at CTRAL. All data will be recorded in Case Report Form and stored in the Texas A\&M REDCap System. Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening day, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, The Six-Minute Walk Test (6MWT) and skeletal muscle function tests will be assessed at the end of each screening visit. Each study visit will begin with vital signs. Before administration of the feeding or the tracer solution, baseline blood will be collected for measurement of the natural enrichment of metabolites. After the baseline sample is collected, feeding will begin and will be followed by tracers of several compounds that may be administered by IV pulse. Participants will receive the liquid nutritional supplement as sip feeds every 20 minutes for 5 hours. The liquid nutrition supplements will contain the following proteins: (1) 45g of whey protein (dairy based), (2) 45g of soy protein (plant based), (3) 45g of pea protein (plant based), or (4) Placebo (water). Participants will have the option of adding sugar free (SF) vanilla syrup, SF caramel syrup, or SF chocolate syrup to their meals.
- Conditions
- Protein Metabolism
- Being tested
- Whey Protein Isolate 90%, Soy Protein Isolate (90% Protein), Organic Pea Protein Isolate, Placebo (Water)
- Keywords
- Prandial, Sarcopenia, Plant protein, Animal protein
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Whey Protein Isolate 90%Dietary supplement
Commercially available animal based protein powders
Soy Protein Isolate (90% Protein)Dietary supplement
Commercially available plant based protein powders
Organic Pea Protein IsolateDietary supplement
Commercially available plant based protein powders
Placebo (Water)Dietary supplement
Normal drinking water
| Study group | Role | What they receive |
|---|---|---|
| Healthy male older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water Receives: Dietary Supplement: Whey Protein Isolate 90%; Dietary Supplement: Soy Protein Isolate (90% Protein); Dietary Supplement: Organic Pea Protein Isolate; Dietary Supplement: Placebo (Water) |
| Healthy female older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water Receives: Dietary Supplement: Whey Protein Isolate 90%; Dietary Supplement: Soy Protein Isolate (90% Protein); Dietary Supplement: Organic Pea Protein Isolate; Dietary Supplement: Placebo (Water) |
| Healthy male old older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water Receives: Dietary Supplement: Whey Protein Isolate 90%; Dietary Supplement: Soy Protein Isolate (90% Protein); Dietary Supplement: Organic Pea Protein Isolate; Dietary Supplement: Placebo (Water) |
| Healthy female old older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water Receives: Dietary Supplement: Whey Protein Isolate 90%; Dietary Supplement: Soy Protein Isolate (90% Protein); Dietary Supplement: Organic Pea Protein Isolate; Dietary Supplement: Placebo (Water) |
| Sarcopenic male old older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water Receives: Dietary Supplement: Whey Protein Isolate 90%; Dietary Supplement: Soy Protein Isolate (90% Protein); Dietary Supplement: Organic Pea Protein Isolate; Dietary Supplement: Placebo (Water) |
| Sarcopenic female old older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water Receives: Dietary Supplement: Whey Protein Isolate 90%; Dietary Supplement: Soy Protein Isolate (90% Protein); Dietary Supplement: Organic Pea Protein Isolate; Dietary Supplement: Placebo (Water) |
| COPD male older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water Receives: Dietary Supplement: Whey Protein Isolate 90%; Dietary Supplement: Soy Protein Isolate (90% Protein); Dietary Supplement: Organic Pea Protein Isolate; Dietary Supplement: Placebo (Water) |
| COPD female older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water Receives: Dietary Supplement: Whey Protein Isolate 90%; Dietary Supplement: Soy Protein Isolate (90% Protein); Dietary Supplement: Organic Pea Protein Isolate; Dietary Supplement: Placebo (Water) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Protein and amino acid synthesis capacity of plant-based and animal-based protein in older adults with or without sarcopenia measured by the use of stable isotope tracers
A novel stable isotope technique will be used to assess simultaneously the anabolic response and whole body production rates of a variety of amino acids to intake of both dietary proteins in sarcopenic older participants. The samples will be stored in laboratory freezers and the amino acid isotope enrichments and concentrations analyzed by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). The researchers will then conduct LC-MS/MS analysis, peak integration, calculation of amino acid concentrations and whole body productions from raw data, and use the results for preparation of papers for presentation, publication, and final reports. The researchers main hypothesis is that plant-based protein induces less protein anabolism, due to lower whole body production of essential amino acids (EAA) and higher production of non-essential amino acids (NEAA) as compared to dairy protein.
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2024
- Study start1 Feb 2024
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Protein MetabolismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Texas A&M University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marielle PKJ Engelen, PhD, Texas A&M University
- Investigators
- Marielle Engelen, PhD, Principal investigator, Texas A&M UniversityNicolaas Deutz, MD, PhD, Principal investigator, Texas A&M University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06628349
- Sponsor's protocol ID
- 94- Plant Protein Sips
- Status last verified
- Nov 2025
- First submitted
- 26 Apr 2024
- Last updated
- 25 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Data may be shared upon request for up to 6 years beyond completion of the trial based on methods/proposals approved by both parties' institutional review committees. Individual participant data that underlie the results of the trial may be shared after de-identification (text, tables, figures, and appendices). Additional documents available per request include: study protocol, statistical analysis plan, and informed consent. Requests should be directed to Dr. Marielle Engelen (mpkj.engelen@ctral.org).
Publications
Huttl VN, Deutz N, Wierzchowska-McNew RA, Ruebush LE, Engelen M. Whole-body and intracellular arginine metabolism in hypertension: role of disease severity and sex. Am J Hypertens. 2026 May 18:hpag047. doi: 10.1093/ajh/hpag047. Online ahead of print.
PubMed 42149813
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein
- ClinicalTrials.gov ID
- NCT06628349
- Acronym / sponsor ID
- 94- Plant Protein Sips
- Conditions
- Protein Metabolism
- Keywords
- Prandial, Sarcopenia, Plant protein, Animal protein
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Texas A&M UniversityUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 4 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The researchers overall objective is to determine whether plant and animal protein based proteins affect the anabolic responses across aging populations differently due to specific changes in the essential amino acids (EAA) and non-essential amino acids (NEAA) kinetic responses. The researchers central hypothesis is that a high EAA to NEAA ratio in a protein meal is related to higher anabolic response to the meal. The researchers also hypothesize that the type of NEAA in a protein meal also affects the anabolic capacity of the meal. The researchers rationale is that finding the amino acid composition of a meal that will maximally induce protein anabolism will guide novel nutritional approaches to prevent and treat sarcopenia, thereby reducing both overall economic burden and improving individual patient outcomes.
Detailed description
The study will be conducted in sarcopenic and non-sarcopenic older adults, stratified into different age categories. A sip feeding model will be used as it is a good model to establish the anabolic capacity of meals. The researchers hypothesize that plant-based protein induces less protein anabolism, due to lower production of EAA and higher production of non-essential amino acids (NEAA) as compared to dairy protein. The NEAA kinetics will be different between the plant proteins as soy protein has relatively high levels of the NEAA arginine and Pea protein of aspartate/glutamate. The researchers results will guide future nutritional advice on replacing daily protein with plant-based proteins while keeping the overall effects on metabolism comparable for both the EAA and NEAA. The study will take place at the research facility of the Center for Translational Research on Aging and Longevity (CTRAL), Texas A\&M University located in the Human Clinical Research Building ) affiliated with Texas A\&M University. The study involves 1 screening visit of approx. 3 hours, and 4 study days. Some study procedures (e.g., body composition, skeletal muscle function, questionnaires) may be skipped if completed within the past 3 months at CTRAL. All data will be recorded in Case Report Form and stored in the Texas A\&M REDCap System. Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening day, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, The Six-Minute Walk Test (6MWT) and skeletal muscle function tests will be assessed at the end of each screening visit. Each study visit will begin with vital signs. Before administration of the feeding or the tracer solution, baseline blood will be collected for measurement of the natural enrichment of metabolites. After the baseline sample is collected, feeding will begin and will be followed by tracers of several compounds that may be administered by IV pulse. Participants will receive the liquid nutritional supplement as sip feeds every 20 minutes for 5 hours. The liquid nutrition supplements will contain the following proteins: (1) 45g of whey protein (dairy based), (2) 45g of soy protein (plant based), (3) 45g of pea protein (plant based), or (4) Placebo (water). Participants will have the option of adding sugar free (SF) vanilla syrup, SF caramel syrup, or SF chocolate syrup to their meals.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Healthy male older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%, Dietary Supplement: Soy Protein Isolate (90% Protein), Dietary Supplement: Organic Pea Protein Isolate, Dietary Supplement: Placebo (Water)Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water |
| Healthy female older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%, Dietary Supplement: Soy Protein Isolate (90% Protein), Dietary Supplement: Organic Pea Protein Isolate, Dietary Supplement: Placebo (Water)Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water |
| Healthy male old older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%, Dietary Supplement: Soy Protein Isolate (90% Protein), Dietary Supplement: Organic Pea Protein Isolate, Dietary Supplement: Placebo (Water)Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water |
| Healthy female old older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%, Dietary Supplement: Soy Protein Isolate (90% Protein), Dietary Supplement: Organic Pea Protein Isolate, Dietary Supplement: Placebo (Water)Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water |
| Sarcopenic male old older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%, Dietary Supplement: Soy Protein Isolate (90% Protein), Dietary Supplement: Organic Pea Protein Isolate, Dietary Supplement: Placebo (Water)Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water |
| Sarcopenic female old older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%, Dietary Supplement: Soy Protein Isolate (90% Protein), Dietary Supplement: Organic Pea Protein Isolate, Dietary Supplement: Placebo (Water)Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water |
| COPD male older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%, Dietary Supplement: Soy Protein Isolate (90% Protein), Dietary Supplement: Organic Pea Protein Isolate, Dietary Supplement: Placebo (Water)Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water |
| COPD female older adults | Experimental | Dietary Supplement: Whey Protein Isolate 90%, Dietary Supplement: Soy Protein Isolate (90% Protein), Dietary Supplement: Organic Pea Protein Isolate, Dietary Supplement: Placebo (Water)Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water |
Who may qualify
- Ages
- 50 to 95 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 50-95 years old
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD); COPD group only
- Stable body-weight (±5%) for the past 3 months
- Ability to walk, sit down, and stand up (independently or with walking assistance device)
- Willingness to lay supine in bed for up to 6 hours
Key exclusion criteria (17 listed)
- Established diagnosis and active treatment of chronic disease: Insulin dependent diabetes mellitus, active malignancy, heart disease, kidney disease, liver disease, HIV/AIDS, Asthma (moderate to severe), Hep (A,B, or C)
- History of untreated metabolic disease including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Hysterectomy
- Active dependence of alcohol or drugs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Whey Protein Isolate 90%Commercially available animal based protein powders | Dietary supplement | COPD female older adults, COPD male older adults, Healthy female old older adults, Healthy female older adults, Healthy male old older adults, Healthy male older adults, Sarcopenic female old older adults, Sarcopenic male old older adults |
| Soy Protein Isolate (90% Protein)Commercially available plant based protein powders | Dietary supplement | COPD female older adults, COPD male older adults, Healthy female old older adults, Healthy female older adults, Healthy male old older adults, Healthy male older adults, Sarcopenic female old older adults, Sarcopenic male old older adults |
| Organic Pea Protein IsolateCommercially available plant based protein powders | Dietary supplement | COPD female older adults, COPD male older adults, Healthy female old older adults, Healthy female older adults, Healthy male old older adults, Healthy male older adults, Sarcopenic female old older adults, Sarcopenic male old older adults |
| Placebo (Water)Normal drinking water | Dietary supplement | COPD female older adults, COPD male older adults, Healthy female old older adults, Healthy female older adults, Healthy male old older adults, Healthy male older adults, Sarcopenic female old older adults, Sarcopenic male old older adults |
Primary outcome
Protein and amino acid synthesis capacity of plant-based and animal-based protein in older adults with or without sarcopenia measured by the use of stable isotope tracers
Time frame: 4 weeks
A novel stable isotope technique will be used to assess simultaneously the anabolic response and whole body production rates of a variety of amino acids to intake of both dietary proteins in sarcopenic older participants. The samples will be stored in laboratory freezers and the amino acid isotope enrichments and concentrations analyzed by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). The researchers will then conduct LC-MS/MS analysis, peak integration, calculation of amino acid concentrations and whole body productions from raw data, and use the results for preparation of papers for presentation, publication, and final reports. The researchers main hypothesis is that plant-based protein induces less protein anabolism, due to lower whole body production of essential amino acids (EAA) and higher production of non-essential amino acids (NEAA) as compared to dairy protein.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2025.
- Derived from this study: PubMed 42149813Huttl VN, Deutz N, Wierzchowska-McNew RA, Ruebush LE, Engelen M. Whole-body and intracellular arginine metabolism in hypertension: role of disease severity and sex. Am J Hypertens. 2026 May 18:hpag047. doi: 10.1093/ajh/hpag047. Online ahead of print.
- Individual participant dataSharing planned: Undecided. Data may be shared upon request for up to 6 years beyond completion of the trial based on methods/proposals approved by both parties' institutional review committees. Individual participant data that underlie the results of the trial may be shared after de-identification (text, tables, figures, and appendices). Additional documents available per request include: study protocol, statistical analysis plan, and informed consent. Requests should be directed to Dr. Marielle Engelen (mpkj.engelen@ctral.org).
Related trials for Protein Metabolism
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
RecruitingPhase 1
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
Healthy Female Participants
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Enrolling by invitationPhase 2
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
PSP - Progressive Supranuclear Palsy
Active, not recruitingPhase 2
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Multiple Myeloma, AL Amyloidosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marielle Engelen, PhD principal investigator
Texas A&M University
Nicolaas Deutz, MD, PhD principal investigator
Texas A&M University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Whey Protein Isolate 90%, Soy Protein Isolate (90% Protein) and Organic Pea Protein Isolate in people with Protein Metabolism, run by Texas A&M University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marielle Engelen, PhD (979-220-2282, mpkj.engelen@ctral.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Protein and amino acid synthesis capacity of plant-based and animal-based protein in older adults with or without sarcopenia measured by the use of stable isotope tracers (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06628349, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2025.